VANCOUVER, BRITISH COLUMBIA--(Marketwire - 05/26/11) - ALDA Pharmaceuticals Corp. (TSX-V:APH - News)(OTCQB: APCSF) (the “Company” or “ALDA”) has filed its patent application, “Antiseptic Compositions for the Treatment of Infections”, with the US Patent and Trademark Office (Serial #12/933,358). The application, first submitted to the Canadian Intellectual Property office for review in March, 2008 under the Patent Cooperation Treaty, seeks protection for the composition and preparation of T36® formulations that also contain steroids, anesthetics or analgesics for use on topical infections and, in particular, inflamed infections. Typically, infections with associated inflammation are treated with separate antiseptic and anti-inflammatory preparations. The new T36® formulations combine these properties into a single treatment, making the prescription process easier for the physician and the application easier for the patient. Submissions to the European and Canadian patent offices are also planned. This patent is the third in a series of patents providing protection for the T36® technology that have been issued or are pending.
